TRAW — Traws Pharma Inc

Traws Pharma Inc (TRAW) is a biotechnology company listed on NASDAQ. It is led by Iain D. Dukes DPHIL, M.A., Ph.D., based in 12 Penns Trail, Newtown, PA, United States, 18940, with about 4 employees. Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Latest reported TRAW revenue for 2025-09-30 was $2.8M. Net income was $16.6M. Revenue was up 2.1% from 2025-06-30 to 2025-09-30. TRAW currently screens at market cap $12.1M.

Use this TRAW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TRAW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TRAW SEC filings page. Lician reads the product cache first so this HTML stays unique to Traws Pharma Inc even when a live quote feed is slow.